vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and RIVERVIEW BANCORP INC (RVSB). Click either name above to swap in a different company.

RIVERVIEW BANCORP INC is the larger business by last-quarter revenue ($14.0M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). RIVERVIEW BANCORP INC runs the higher net margin — 9.8% vs -1398.3%, a 1408.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 10.4%). RIVERVIEW BANCORP INC produced more free cash flow last quarter ($-736.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 24.6%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Riverview Bancorp Inc. is a U.S.-based bank holding company operating Riverview Community Bank, primarily serving the Pacific Northwest region. It offers personal and commercial banking products including savings accounts, consumer loans, mortgages, commercial lending, and small business financial solutions for retail customers and local enterprises.

RNA vs RVSB — Head-to-Head

Bigger by revenue
RVSB
RVSB
1.1× larger
RVSB
$14.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+423.7% gap
RNA
434.0%
10.4%
RVSB
Higher net margin
RVSB
RVSB
1408.1% more per $
RVSB
9.8%
-1398.3%
RNA
More free cash flow
RVSB
RVSB
$156.1M more FCF
RVSB
$-736.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
24.6%
RVSB

Income Statement — Q3 FY2025 vs Q3 FY2026

Metric
RNA
RNA
RVSB
RVSB
Revenue
$12.5M
$14.0M
Net Profit
$-174.4M
$1.4M
Gross Margin
Operating Margin
-1513.5%
12.4%
Net Margin
-1398.3%
9.8%
Revenue YoY
434.0%
10.4%
Net Profit YoY
-117.0%
11.8%
EPS (diluted)
$-1.27
$0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
RVSB
RVSB
Q4 25
$14.0M
Q3 25
$12.5M
$13.6M
Q2 25
$3.8M
$13.3M
Q1 25
$1.6M
$12.9M
Q4 24
$3.0M
$12.7M
Q3 24
$2.3M
$12.8M
Q2 24
$2.0M
$12.2M
Q1 24
$3.5M
$9.0M
Net Profit
RNA
RNA
RVSB
RVSB
Q4 25
$1.4M
Q3 25
$-174.4M
$1.1M
Q2 25
$-157.3M
$1.2M
Q1 25
$-115.8M
$1.1M
Q4 24
$-102.3M
$1.2M
Q3 24
$-80.4M
$1.6M
Q2 24
$-70.8M
$966.0K
Q1 24
$-68.9M
$-3.0M
Operating Margin
RNA
RNA
RVSB
RVSB
Q4 25
12.4%
Q3 25
-1513.5%
10.2%
Q2 25
-4448.7%
11.7%
Q1 25
-8360.9%
11.3%
Q4 24
-4069.6%
12.4%
Q3 24
-4200.9%
15.5%
Q2 24
-4040.4%
10.0%
Q1 24
-2178.6%
-47.5%
Net Margin
RNA
RNA
RVSB
RVSB
Q4 25
9.8%
Q3 25
-1398.3%
8.1%
Q2 25
-4089.3%
9.2%
Q1 25
-7360.0%
8.9%
Q4 24
-3439.5%
9.7%
Q3 24
-3441.7%
12.2%
Q2 24
-3461.8%
7.9%
Q1 24
-1943.4%
-34.7%
EPS (diluted)
RNA
RNA
RVSB
RVSB
Q4 25
$0.07
Q3 25
$-1.27
$0.05
Q2 25
$-1.21
$0.06
Q1 25
$-0.90
$0.05
Q4 24
$-0.80
$0.06
Q3 24
$-0.65
$0.07
Q2 24
$-0.65
$0.05
Q1 24
$-0.79
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
RVSB
RVSB
Cash + ST InvestmentsLiquidity on hand
$350.2M
$28.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$164.2M
Total Assets
$2.1B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
RVSB
RVSB
Q4 25
$28.6M
Q3 25
$350.2M
$32.8M
Q2 25
$243.9M
$34.2M
Q1 25
$254.2M
$29.4M
Q4 24
$219.9M
$25.3M
Q3 24
$370.2M
$31.0M
Q2 24
$575.8M
$27.8M
Q1 24
$471.4M
$23.6M
Stockholders' Equity
RNA
RNA
RVSB
RVSB
Q4 25
$164.2M
Q3 25
$1.9B
$163.5M
Q2 25
$1.2B
$162.0M
Q1 25
$1.3B
$160.0M
Q4 24
$1.4B
$158.3M
Q3 24
$1.5B
$160.8M
Q2 24
$1.2B
$155.9M
Q1 24
$830.9M
$155.6M
Total Assets
RNA
RNA
RVSB
RVSB
Q4 25
$1.5B
Q3 25
$2.1B
$1.5B
Q2 25
$1.4B
$1.5B
Q1 25
$1.5B
$1.5B
Q4 24
$1.6B
$1.5B
Q3 24
$1.6B
$1.5B
Q2 24
$1.3B
$1.5B
Q1 24
$951.5M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
RVSB
RVSB
Operating Cash FlowLast quarter
$-156.2M
$-506.0K
Free Cash FlowOCF − Capex
$-156.9M
$-736.0K
FCF MarginFCF / Revenue
-1257.6%
-5.2%
Capex IntensityCapex / Revenue
5.7%
1.6%
Cash ConversionOCF / Net Profit
-0.37×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$20.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
RVSB
RVSB
Q4 25
$-506.0K
Q3 25
$-156.2M
$16.8M
Q2 25
$-199.7M
$-697.0K
Q1 25
$-124.8M
$8.3M
Q4 24
$-99.9M
$2.2M
Q3 24
$-65.6M
$764.0K
Q2 24
$-65.0M
$5.4M
Q1 24
$-70.4M
$12.8M
Free Cash Flow
RNA
RNA
RVSB
RVSB
Q4 25
$-736.0K
Q3 25
$-156.9M
$16.4M
Q2 25
$-203.0M
$-773.0K
Q1 25
$-128.6M
$5.6M
Q4 24
$-103.8M
$1.9M
Q3 24
$-67.3M
$-1.4M
Q2 24
$-65.5M
$5.3M
Q1 24
$-71.3M
$7.1M
FCF Margin
RNA
RNA
RVSB
RVSB
Q4 25
-5.2%
Q3 25
-1257.6%
120.1%
Q2 25
-5277.1%
-5.8%
Q1 25
-8174.3%
43.1%
Q4 24
-3491.0%
15.0%
Q3 24
-2881.8%
-11.3%
Q2 24
-3204.6%
43.7%
Q1 24
-2012.3%
79.0%
Capex Intensity
RNA
RNA
RVSB
RVSB
Q4 25
1.6%
Q3 25
5.7%
2.9%
Q2 25
86.9%
0.6%
Q1 25
238.6%
21.0%
Q4 24
131.7%
2.4%
Q3 24
72.9%
17.3%
Q2 24
26.0%
0.9%
Q1 24
25.8%
62.0%
Cash Conversion
RNA
RNA
RVSB
RVSB
Q4 25
-0.37×
Q3 25
15.25×
Q2 25
-0.57×
Q1 25
7.20×
Q4 24
1.79×
Q3 24
0.49×
Q2 24
5.63×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons